Boston Scientific Corp (BSX)vsSera Prognostics Inc (SERA)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
SERA
Sera Prognostics Inc
$2.03
+11.54%
HEALTHCARE · Cap: $70.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 24782616% more annual revenue ($20.07B vs $81,000). BSX leads profitability with a 14.4% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
SERA
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Intrinsic value data unavailable for SERA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : SERA
The strongest argument for SERA centers on Price/Book, Debt/Equity.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : SERA
The primary concerns for SERA are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
BSX profiles as a growth stock while SERA is a value play — different risk/reward profiles.
SERA carries more volatility with a beta of 1.02 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 27/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Sera Prognostics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sera Prognostics Inc. is a pioneering healthcare company focused on advancing maternal-fetal health through innovative diagnostic solutions. Leveraging its proprietary biomarker platform, Sera developed the PreTRM test to assess the risk of preterm birth, enabling timely clinical interventions that can significantly improve pregnancy outcomes. With a strong emphasis on collaboration with healthcare providers, Sera is poised to lead the prenatal diagnostics market, enhancing both maternal health and overall societal well-being. The company's dedication to innovation not only aims to foster healthier pregnancies but also seeks to generate long-term value for its investors.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?